A retrospective study to assess real-world efficacy and safety of pembrolizumab in pre-treated NSCLC patients and the clinical utility of Lung Immune Prognostic Index for patients selection
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Jul 2022 New trial record
- 04 Jul 2022 Results published in the Targeted Oncology